42C — IX Biopharma Share News
0.000.00%
Last trade - 00:00- SG$520.60m
- SG$511.67m
- SG$6.85m
Brief: IX Biopharma Set To Expand Its Current Wafer Production Capacity At Facility In Australia
Brief: Ix Biopharma Granted Orphan Drug Designation Granted For Treatment Of CRPS With Ketamine
Brief: IX Biopharma Entered Into Agreement With China Resources Pharmaceutical Commercial Group
Advisory: Multiple dated alerts withdrawn
Brief: IX Biopharma Says Received Positive Feedback From European Medicines Agency Regarding Wafermine
Brief: IX Biopharma Obtains Approval And Registration Of Silcap In Singapore
Brief: IX Biopharma Secures Israel Patent For Waferix Drug Delivery Technology
Brief: Ix Biopharma Requests For Trading Halt
Brief: IX Biopharma Gets Allowance Notice From U.S. Patent And Trademark Office For Application
Brief: Ix Biopharma Says Ix Syrinx Formalises Supply Agreement With Cannatrek Medical Pty
Brief: IX Biopharma Enters Licensing Agreement With Yiling Pharmaceutical
Brief: iX Biopharma Secures Australian Cannabis Manufacture Licence
Brief: Ix Biopharma Says Co & FDA Reached Agreement On Key Aspects Of A Phase 3 Clinical Trial
Brief: iX Biopharma Says Granted Cannabis Manufacture Licence From Office Of Drug Control In Australia
Brief: IX Biopharma Posts QTRLY Loss From Cont. Ops S$2.8 MLN
Brief: iX Biopharma To Dispose Laboratory Testing Business For A$12.5 Mln
Brief: IX Biopharma Posts QTRLY Loss S$3.6 MLN
Brief: Ix Biopharma Reports Positive Results From Wafermine Clinical Trial
Brief: IX Biopharma Obtains Approval And Registration Of Wafesil In Australia